Compare MCI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | OABI |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.9M | 391.4M |
| IPO Year | N/A | N/A |
| Metric | MCI | OABI |
|---|---|---|
| Price | $17.72 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 35.0K | ★ 517.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $9.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.57 | $1.32 |
| 52 Week High | $23.00 | $2.79 |
| Indicator | MCI | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 60.17 |
| Support Level | $17.27 | $1.42 |
| Resistance Level | $18.08 | $2.79 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 70.00 | 87.70 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.